Lightpoint Medical Announces $8 Million in Funding to Support Commercial Launch of its Robotic Cancer Detection Probe
Lightpoint Medical, a medical device company developing miniaturized cancer detection tools for robot-assisted surgery, announced today that it has completed an $8 million financing round. The funding includes follow-on investment from private investors, Oxford Technology, Venture Founders, Coutts Bank, and new funding from the British Business Bank Future Fund, bringing the total raised by the company to $18 million.
The new capital will be used to finance expanded clinical trials and early commercialization of Lightpoint’s robotic probe, SENSEI®, which has the potential to assist in over 2 million applicable surgical procedures every year in the EU, US, China and Japan.
SENSEI® received CE Mark approval at the beginning of the year, has been registered successfully with the FDA, and has received approval for sale in Australia.
Lightpoint has secured commercial distribution deals for SENSEI® in Spain, Portugal, and Australia. With more contracts to be announced in the forthcoming months, Lightpoint intends to establish a global distribution network by the end of 2021.
Clinical trials of SENSEI® in robotic surgery are ongoing in prostate and cervical cancer with new studies in lung cancer planned for the second half of the year.
